Aktis Oncology, Inc. (AKTS) Stock Statistics & Valuation Metrics

Aktis Oncology, Inc. has a market cap or net worth of $1.32B. The enterprise value is $896.56M.

Aktis Oncology, Inc. has 53,404,617 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aktis Oncology, Inc.’s return on equity (ROE) is 0.44 and return on invested capital (ROIC) is -31.79%.

The current PE Ratio of Aktis Oncology, Inc. is ―. Aktis Oncology, Inc.’s PEG ratio is 3.39.

In the last 12 months, Aktis Oncology, Inc. had revenue of 6.50M and earned -63.73M in profits. Earnings per share was -1.19.

In the last 12 months, operating cash flow was -39.48M and capital expenditures -6.01M, giving a free cash flow of -45.49M billion.

Aktis Oncology, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Aktis Oncology, Inc. upcoming earnings date is May 11, 2026, After Close (Confirmed).

Aktis Oncology, Inc. as a current ratio of 7.37, with Debt / Equity ratio of 2.29%

In the past 12 months, Aktis Oncology, Inc. has paid 0.00 in taxes.

Aktis Oncology, Inc. EV to EBITDA ratio is -18.73, with an EV/FCF ratio of -15.61.

Aktis Oncology, Inc. has $538.48M in cash and marketable securities with $11.58M in debt, giving a net cash position of $526.91M billion.

Gross margin is 87.21%, with operating margin of -1149.52%, and net profit margin of -980.93%.

The average price target for Aktis Oncology, Inc. is $35.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy